JPRN-UMIN000022804已完成4 期
The efficacy of SGLT2 inhibitor switching from thiazolidine about body weight and metabolic-related factors in type 2 diabetes patients - The efficacy of SGLT2 inhibitor switching from thiazolidine in type 2 diabetes patients
Hokkaido Unverstiy Hospital0 个研究点目标入组 70 人开始时间: 2016年6月20日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Already taking SGLT2 inhibitor agents 2) With hypersensitivity to Dapagliflozin 3) With severe or unstable retinopathy 4) With severe liver or kidney disfunction 5) With severe diabetic ketosis, pre-coma, or coma 6) With severe infection or trauma, or in perioperation 7) With pregnancy 8) Patients who thought to be inappropriate to enter this study for some reasons by physician's judgments
研究者
相似试验
招募中
4 期
Efficacy of SGLT2 inhibitor for Non-Alcoholic Fatty Liver Diseaseon Alcoholic Fatty Liver DiseaseC06.552.241.519C18.452.394.750.149ObesityType 2 Diabetes MellitusRBR-48rxwbCentro Educacional Hyarte
尚未招募
Unknown
Influence of SGLT2 inhibitors on the efficiency of peritoneal dialysisChronic kidney disease under peritoneal dialysisJPRN-UMIN000049848International University of Health and Welfare10
已完成
不适用
The efficacy and safety of SGLT2 inhibitor for non alcholic fatty liver disease in Japanese patients with type 2 diabetesJPRN-UMIN000016306Tokyo Medical and Dental University50
已完成
不适用
Effects of treatment with SGLT2 inhibitor on the initiation of continuous positive airway pressure therapy in type 2 diabetic patients with obstructive sleep apnea syndromeType 2 diabetesJPRN-UMIN000045226Akishima Clinic16
已完成
不适用
Efficacy and safety in SGLT2 inhibitor for non-diabetes complicated by non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.JPRN-UMIN000031041Kobe university school of medicine, Diabetes and Endocrinoplogy30